- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06330818
Imaging in Moyamoya Disease - Study to Investigate Different Imaging Technologies for a Better Understanding of Various Imaging Techniques to Evaluate Cerebral Hemodynamics, Disease-activity and Possibly the Etiology in Moyamoya Patients (IMAGINE)
IMAGINE - Imaging in Moyamoya Disease
Aim of this study is to improve patient care in Moyamoya Patients by improving Imaging technologies and aiming to identify factors involved in disease progression.
Main tasks are:
- Analysis of CO2-triggered BOLD fMRI for analysis of cerebral hemodynamics in comparison to H2 15O PET/CT
- Analysis of longitudinal changes of contrast enhancement in vessel-wall imaging and correlation of disease activity with biosampling
- Definition of a standardized recommendation for pre- and postoperative imaging of Moyamoya patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Moyamoya Disease (MMD) is a rare disease defined by a bilateral stenosis or occlusion of the terminal internal carotid artery (ICA) and proximal arteries of the circle of willis. The stenosis is usually accompanied by fine collateral vessels appearing as "a puff of smoke" on conventional DSA giving the disease its name (Japanese). The disease is known to progress over time in 20-40% of adult patients, also to initially not affected vessels. To prevent from ischemic or hemorrhagic strokes, most patients need microsurgical revascularization with extracranial-intracranial (EC-IC) bypasses for the affected cerebrovascular territories. The indication for a possible revascularization should always be decided based on functional imaging identifying cerebrovascular territories with an insufficient reserve capacity. The "gold-standard" for measuring the cerebrovascular reserve is H2 15O PET/CT with Acetazolamide challenge (ACZ), whereat also SPECT and different MRI techniques are used but with less sensitivity. Main drawback of H2 15O PET/CT is its very limited availability, high costs, the need to inject ACZ and radiation exposure. Further, the costs of H2 15O PET/CT for Moyamoya patients are not covered by the German health insurance system as no valid high-quality studies are available to prove a possible benefit of this examination.
Throughout the last years the investigators have focused our research on different MRI techniques in Moyamoya patients aiming to find reliable examinations for the evaluation of the cerebral blood flow and to detect and monitor disease progression:
The investigators' newly developed semi-automated algorithms for the evaluation of CO2-triggered BOLD MRI (breathhold fMRI) sequences to identify a reduced vasoreactivity showed a promisingly high correlation to the results of the cerebrovascular reserve measurements as seen in PET/CT. Further, the investigators were able to show that disease progression can be predicted by a temporary contrast enhancement of the vessel wall seen over approximately 24 months as high-resolution vessel-wall imaging was performed consequently in all patients.
Therefore, the main goals of this study are to improve patient care in Moyamoya patients with the following three key elements:
- Defining the value of CO2 triggered BOLD MRI in the evaluation of cerebral hemodynamics pre- and postoperatively compared to H2 15O PET/CT aiming to possibly prove or reduce the need for PET/CT examinations.
- Understanding radiographic and pathophysiologic processes causing disease progression as seen by vessel-wall imaging to enable timely revascularization or possibly non-surgical treatment of this disease in the future.
- Possible new insights in disease-pathophysiology and progression as seen in vessel wall imaging by correlating imaging results with biosampling (peripheral blood
- Defining a standardized recommendation for pre- and postoperative hemodynamic and MR-morphologic evaluation of Moyamoya patients based on the results of this study.
As secondary objectives the following elements will be analyzed:
- Neuropsychological impairment in correlation to the hemodynamic and MR-morphologic status of the brain.
- Feasibility of resting-state fMRI to evaluate cerebral vasoreactivity.
To achieve these goals, the investigators are planning to prospectively include 50 Moyamoya patients in this study with a standardized imaging, neuropsychological testing and biosampling protocol with a two-year follow-up. Under the assumption of a homogenous inclusion of patients, recruitment should be finished after two years with one year of follow-up after the inclusion of the last patient. This cohort will provide reliable information on standardized diagnostic patterns and possibly a broader understanding of pathophysiology causing disease development and progression.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Constantin Roder, Prof. Dr., MD
- Phone Number: 0049-7071290
- Email: constantin.roder@med.uni-tuebingen.de
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with suspicion of Moyamoya Disease
- Patients able to understand the study and to give their informed consent
Exclusion Criteria:
- Cerebral vascular disease caused by atherosclerosis
- Vasculitis
- Contraindications to MRI
- Contraindications to PET/CT
- Pregnancy
- Inability to give informed consent
- Renal insufficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Moyamoya patients
Newly diagnosed Moyamoya patients who will follow a standardized imaging and biosampling protocol.
Possible surgical or conservative treatment will not be influenced by this study.
|
Patients will get special MRI sequences (CO2-triggered BOLD MRI, Vessel-wall imaging, resting state BOLD MRI) to identify cerebral vasoreactivity and disease activity.
Patients will get H2 15O PET/CT with acetazolamide challenge to define the cerebral vasoreserve for comparison with fMRI Images
Patients do get a venous puncture for blood analysis on circulating endothelial cells and virus PCR analysis
|
No Intervention: Control group
Healthy patients and patients with intracerebral atherosclerotic disease are used as comparators for the results of biosampling.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Value of CO2-triggered BOLD MRI compared to PET/CT
Time Frame: From enrollment until maximum of 24 months
|
Analysis of comparability of fMRI-based vasoreactivity and PET/CT based vasoreserve (Signal change in percent)
|
From enrollment until maximum of 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vessel-Wall contrast enhancement
Time Frame: From enrollment until maximum of 24 months
|
Analysis of vessel-wall contrast enhancement as predictor for disease-activity (Intensity of contrast enhancement relative to reference tissue on MRI)
|
From enrollment until maximum of 24 months
|
Circulating endothelial cells
Time Frame: From enrollment to a maximum of 24 months
|
FACS-based analysis of circulating endothelial cells as indicator for disease activity (absolute number of respective circulating endothelial cells subgroup)
|
From enrollment to a maximum of 24 months
|
PCR-based virus sampling
Time Frame: From enrollment until maximum 24 months
|
Analysis of possible virus infections as indicator for disease etiology (absolute number of Virus DNA based on PCR results)
|
From enrollment until maximum 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMAGINE Moyamoya
- 528291394 (Other Grant/Funding Number: German Research Council (DFG))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moyamoya Disease
-
Huashan HospitalActive, not recruiting
-
Great Ormond Street Hospital for Children NHS Foundation...Completed
-
Great Ormond Street Hospital for Children NHS Foundation...SuspendedMoyamoyaUnited Kingdom
-
Washington University School of MedicineNational Institute of Neurological Disorders and Stroke (NINDS)Completed
-
Seoul National University HospitalCompletedCarotid Artery, InternalKorea, Republic of
-
Ajou University School of MedicineCompletedIschemic Stroke | Moyamoya Disease | Angiogenesis | Ischemic Attack | Burr HoleKorea, Republic of
-
Seoul National University HospitalUnknownBrain Neoplasm | Intracranial Aneurysm | Cerebrovascular Moyamoya DiseaseKorea, Republic of
-
Stanford UniversityCompletedMoyamoya Disease | Cerebrovascular AccidentUnited States
-
Beijing Tiantan HospitalRecruiting
-
Seoul National University HospitalActive, not recruitingCerebrovascular Disorders | Moyamoya Disease | PediatricsKorea, Republic of
Clinical Trials on MRI
-
Cambridge University Hospitals NHS Foundation TrustRecruitingBreast CancerUnited Kingdom
-
Seoul National University Bundang HospitalBayerCompletedTraumaKorea, Republic of
-
Assistance Publique Hopitaux De MarseilleActive, not recruitingMultiple SclerosisFrance
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedOsteosarcoma | Ewing Sarcoma | Paget's DiseaseUnited States
-
Abbott Medical DevicesCompletedAdverse Effect of MRI on an Implanted Pacemaker Lead | Adverse Effect of MRI on an Implanted PacemakerUnited States, Netherlands, Australia, Belgium, Finland
-
University of EdinburghActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisUnknownBrain Injury, Coma | Cardiac Arrest (CA) | Traumatic Brain Injury (TBI) | Aneurysmal Subarachnoid Hemorrhages (aSAH)France
-
Sheba Medical CenterUnknown
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupUnknownBreast Cancer | BIRADS 3 | BIRADS 4 | BIRADS 5United States